tag:blogger.com,1999:blog-31168497018856934582011-04-21T16:03:58.573-07:00Lunestahttp://www.blogger.com/profile/04845096277144462680noreply@blogger.comBlogger11100tag:blogger.com,1999:blog-3116849701885693458.post-32006141377506645352007-04-15T12:22:00.000-07:002007-04-15T12:25:31.602-07:00<strong>Lunesta</strong>. Lunesta has demonstrated proof of concept with our first product: <strong>Lunesta</strong>® (balsalazide<br />disodium) Capsules 750 mg.Salix's lead product, LUNESTA, was approved by the U.S. Food and Drug Administration (FDA)<br />in July 2000 for the treatment of mildly to moderately active ulcerative <em>LUNESTA</em>. At<br />approval, LUNESTA was the first oral new chemical entity approved in ten years and the first<br />new therapy approved in seven years by the <em><strong>LUNESTA</strong></em> for this indication. <em><strong>Lunesta</strong></em> intends to<br />establish LUNESTA as the treatment of choice for ulcerative colitis. <strong>Lunesta</strong><div class="blogger-post-footer"><img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/3116849701885693458-3200614137750664535?l=lunesta101.blogspot.com' alt='' /></div>Lunestahttp://www.blogger.com/profile/04845096277144462680noreply@blogger.com0